Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. [electronic resource]
Producer: 20041207Description: 1735-41 p. digitalISSN:- 0007-0920
- Animals
- Antineoplastic Agents -- therapeutic use
- Benzamides
- Cell Proliferation -- drug effects
- DNA-Activated Protein Kinase
- DNA-Binding Proteins -- antagonists & inhibitors
- Drug Resistance, Neoplasm
- Enzyme Inhibitors -- therapeutic use
- Fusion Proteins, bcr-abl
- Gene Expression Regulation, Leukemic
- Humans
- Imatinib Mesylate
- Leukemia, Erythroblastic, Acute -- drug therapy
- Mice
- Mice, Nude
- Neoplasm Recurrence, Local -- drug therapy
- Nuclear Proteins
- Phosphorylation
- Piperazines -- pharmacology
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- metabolism
- Proto-Oncogene Proteins c-akt
- Pyrimidines -- pharmacology
- Tumor Cells, Cultured
- Tyrphostins -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.